Tillkännagivande • Feb 25
OptiBiotix Health plc Announces Commencement of Clinical Study with Hull University Teaching Hospital Nhs Trust OptiBiotix Health plc announced the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings. A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have systemic anti-inflammatory effects, may improve surgical outcomes. This double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications. The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of prebiotic like WellBiome in improving health outcomes and cost savings. WellBiome is a patented mineral-enriched prebiotic fibre complex developed in collaboration with leading UK Universities to enhance gut microbiome diversity greater than single prebiotic fibres alone. WellBiome has a number of European and USA on pack health claims including: Nourishes beneficial bacteria throughout the entire gut to improve gut health; Contributes to improved bone health by aiding the absorption of essential minerals; Contributes to normal muscle function, including heart muscle; Supports normal brain health function and memory; Contributes to normal psychological function; Supports cardiovascular health; Contributes to a reduction of tiredness and fatigue. Tillkännagivande • Nov 24
OptiBiotix Health Plc Provides Update on its SweetBiotix Product Range for New and Existing Investors OptiBiotix Health plc provided an overview and update on its SweetBiotix product range for new and existing investors. SweetBiotix®? are a portfolio of natural, sweet, high fibre, low-calorie products developed to replace sugar and sugar substitutes. They are produced using a patented technology developed by OptiBiotix which enzymatically modifies existing natural sweeteners like steviol glycosides and mogrosides and converts them into dietary fibres, providing sweetness with added nutritional and health benefits. SweetBiotix are trademarked and patented products protected by a significant intellectual property portfolio comprising over 25 patents with a number of recent additional filings. Patients must demonstrate novelty/uniqueness, inventiveness (i.e. no one else has invented it), and industry applicability confirming the uniqueness of SweetBiotix. SweetBiotix are unique as a sugar substitute as they have been developed to overcome health concerns, are high in fibre, and have prebiotic functionality providing nutritional and health benefits not present in existing products. This a market estimated to be worth $29.9 billion by 2029 (Markets and Markets: Oct 2024). What is the evidence that SweetBiotix are sweet and have health benefits SweetBiotix products have been tested by academic groups who have published five papers in peer reviewed journals providing an independent assessment of SweetBiotix's taste and health benefits. One publication on an early SweetBiotix product concluded ' This new ingredient could provide health benefits when evaluated in human studies by combining sweetness and prebiotic fiber functionality'. The Company has provided SweetBiotix samples under Material Transfer Agreements (MTA) to a number of partners, many of whom have specialist expertise in taste testing and sugar substitutes. This has led to a formal agreement with a USA partner and DSM Firmenich, a $12 billion ingredients supplier, and several food and beverage companies supporting SweetBiotix development with a view to the use of SweetBiotix in their products. This changes the positioning with sugar producers who have previously seen SweetBiotix as a competitor, to a potential partner, by offering a unique, patented process which can utilise and modify commoditised sucrose into higher valued SweetBiotix products. Importantly, whilst there is a material change in the enzymatic process there is no change to the resulting SweetBiotix product other than higher yields which significantly increases the purity (90%) of the final product. The Company believes that most of the process changes are covered within its existing patent portfolio but has extended its filings on the enzyme use and composition given the uniqueness and commercial potential of their properties. Next steps The Company is producing quantities of SweetBiotix for its development, manufacturing, and application partners and sharing the new enzymatic process with DSM Firmenich, US partner, and major sugar producers given its potential to valorise sugar. The Company continues to receive an annual milestone of PS100k from its US partner related to work on Mogrosides with total received to end of 2024 of PS550k. Milestone payments are rarely seen in the food, beverage and supplement industry, even less so prior to commercial launch and should give investors' confidence in the value attributed to this technology by industry. Subject to any partner constraints, the Company hopes to be in a position to demonstrate a range of SweetBiotix products to investors in first first half of 2026. Subject to any partner restrictions, the Company hopes to be In addition to any partner constraints, the company hopes to be in a positions to demonstrate a range of Sweet Biotix products to investors in H1 2026. The Company has made a breakthrough in improving the manufacturing process of its SweetBiotix products. By using a new enzyme, rather than an enzyme extract, the Company is able to achieve substantially higher yields of a purer, more concentrated, better tasting product with lower ingredient and production costs. These are significant benefits when producing at large scale. This new enzyme works on both mogrosides and stevia glycosides allowing the generation of multiple SweetBiotix products to multiple SweetBiotix products. Tillkännagivande • Jun 29
OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024 OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024. Location: the offices of peterhouse capital limited, 3rd floor, 80 cheapside, ec2v 6ee, london United Kingdom Tillkännagivande • Jun 21
OptiBiotix Health Plc Announces Slimbiome Study Results OptiBiotix Health plc notes the latest results from the human studies carried out at Roehampton University, London on OptiBiotix's SlimBiome. Study outcomes, awaiting publication, suggested SlimBiome® intake had a major impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness within 15 minutes, for over two hours after consumption. This is one of four studies which have consistently shown SlimBiome® reduces hunger and food cravings leading to users both reducing the amount of food and changing the type of food they eat, to less calorie intense food leading to sustainable weight management. This suggests that SlimBiome® can be used as a natural alternative to the current anti-obesity drugs on the market. These findings on the acute impact of one dose of SlimBiome® are consistent with those of a previous first study, also carried out by Professor Adele Costabile, published in the Journal of Functional Foods (November 2020) which showed that volunteers taking SlimBiome® for four weeks experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. SlimBiome® is availableherein sachets as SlimBiome Medical®/SlimBiome X3 or in meal replacements, bars, gummies, and soups/porridges and is increasingly being used by major sports nutrition brands to support lean body development. The latest results from human studies reinforce findings that a mineral enriched prebiotic fibre complex can help reduce hunger by 27% and support the feeling of fullness by 35% offering a rapid and natural solution for those seeking support in weight management. The latest results from a study conducted by Professor Adele Costabile at the University of Roehampton using Optibitix's SlimBiome® saw 20 volunteers given 50g (12 teaspoons) of sugar with and without SlimBiome®. Study outcomes, awaiting publication, suggested SlimBiome® intake had a significant impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness for over two hours after consumption. These findings on the acute impact of one dose of SlimBiome are consistent with those of a previous first study, also carried out by Professor Adele and her team, published in the Journal of Functional Foods (November 2020) which showed that taking SlimBiome® for four weeks volunteers experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. Overall, 90% of volunteers lost weight and all volunteers reported a reduction in waist and hip circumference and lost body fat. In addition, volunteers improved their mood by 26%, suggesting they were losing weight without feeling hungry or craving for food making it more sustainable. The results also showed a significant change in volunteers gut microbiome with a statistically significant increase in microbes associated with a lean body. These studies suggest that a natural ingredient like SlimBiome®, which was tolerated well in all studies, may offer a natural approach to managing hunger and food cravings to support weight management. Whilst using different mechanisms of action, SlimBiome® and anti-obesity drugs work in a similar way by regulating insulin response and promoting the feelings of fullness by slowing down stomach emptying. Tillkännagivande • Jan 15
OptiBiotix Health PlcAnnounces Launch of LeanBiome in Muscletech OptiBiotix Health plc announced the forthcoming launch of LeanBiome in Muscletech,one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company. The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK. Muscletech®is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world.LeanBiome® will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and willbe launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels. LeanBiome®is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome®contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness (Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes. Tillkännagivande • Dec 04
Optibiotix Health plc Appoints Graham Myers as Finance Director OptiBiotix Health Plc announces that Graham Myers has been appointed as Finance Director of the Company as of 1 December 2023. Graham is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial and commercial experience in a number of private and public companies, including being a member of the Executive Committee at Croda International Plc, where he worked for almost 30 years. Graham brings extensive experience in optimising financial controls, managing budgets, building profitable businesses and mergers & acquisitions. Graham is currently Chair of Croda Pension Trustees Limited, the sole trustee of Croda's £800m UK pension scheme. Graham's appointment to this part-time role will see him work closely with the OptiBiotix team to support thefocus on driving each business unit and the Group to profitability. 